Technology Development

A defining strength of the Department of Genetics and Genomic Sciences (GGS) is our strong focus on the development and integration of cutting-edge genomic technologies. These tools are not siloed—they are seamlessly embedded across the research programs of our faculty and play a central role in advancing both discovery science and clinical translation.

Ongoing advances in genome editing, sequencing, and functional characterization have transformed our understanding of the genome, epigenome, and transcriptome. These innovations continue to accelerate progress in fields such as precision medicine, oncology, immunology, neuroscience, and infectious disease.

GGS researchers are leading the development and application of multi-omic methods across model systems and patient cohorts to address complex biological questions. By integrating bulk and long-read sequencing, single-cell analysis, open chromatin profiling, and spatial transcriptomics, we have generated insights into the molecular basis of drug addiction, cancer immunotherapy response, Alzheimer’s disease, and COVID-19.

The department is supported by a robust infrastructure of genomic technologies, including:

  • Ultra-low-input library preparation for limited or degraded samples
  • Targeted gene profiling for DNA and RNA applications
  • Amplification-free Cas9-based enrichment strategies
  • Short-read and long-read sequencing platforms, spanning single-molecule and nanopore techniques, applied across bulk samples, single cells, and intact tissues

These tools are coupled with deep domain expertise in experimental design, innovative technology applications, and bioinformatic analysis. As a department, we continually push the boundaries of genomic science, generating new data and methodologies that shape the future of research at the Icahn School of Medicine at Mount Sinai and through global collaborations.

Genetics and Genomic Sciences Faculty